These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39254006)

  • 1. Switch from methadone to buprenorphine with microinduction in outpatient setting.
    Juya F; Askjer JF; Dahl LMK; Holtan L; Mordal J
    Tidsskr Nor Laegeforen; 2024 Sep; 144(10):. PubMed ID: 39254006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".
    Singh G; Sri Konakanchi J; Betsch B; Thapa A; Sethi R
    J Opioid Manag; 2021; 17(7):167-170. PubMed ID: 34520038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
    Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
    J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community based buprenorphine micro-induction in the context of methadone maintenance treatment and fentanyl - Case report.
    Kaliamurthy S; Jegede O; Hermes G
    J Addict Dis; 2023; 41(2):175-180. PubMed ID: 35377273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
    Terasaki D; Smith C; Calcaterra SL
    Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
    Mannelli P; Peindl KS; Lee T; Bhatia KS; Wu LT
    Curr Drug Abuse Rev; 2012 Mar; 5(1):52-63. PubMed ID: 22280332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine Enhanced Taper Tolerability Evaluation Report (BETTER): A Case Series.
    Epland C; Pals H; Hayden J
    Subst Use Addctn J; 2024 Oct; 45(4):765-770. PubMed ID: 38591225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder.
    Salapenka I; Konakanchi JS; Sethi R
    Prim Care Companion CNS Disord; 2022 Dec; 24(6):. PubMed ID: 36584361
    [No Abstract]   [Full Text] [Related]  

  • 12. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.
    De Aquino JP; Parida S; Sofuoglu M
    Clin Drug Investig; 2021 May; 41(5):425-436. PubMed ID: 33818748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.
    Callan J; Pytell J; Ross J; Rastegar DA
    J Addict Med; 2020; 14(5):e274-e276. PubMed ID: 31977358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy.
    Oretti R
    J Subst Abuse Treat; 2015 Oct; 57():102-5. PubMed ID: 26048187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone Induction for a Patient With Precipitated Withdrawal in the Emergency Department: A Case Report.
    Church B; Clark R; Mohn W; Potee R; Friedmann P; Soares WE
    J Addict Med; 2023 May-Jun 01; 17(3):367-370. PubMed ID: 37267195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.